This article first appeared on GuruFocus .
Release Date: May 13, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
MediPharm Labs Corp ( MEDIF ) returned to positive adjusted EBITDA in Q1 2026, demonstrating improved margin quality and lower operating expenses.
-
The company holds a unique combination of licenses, including Health Canada drug establishment license and EU GMP certification, which differentiates it in regulated medical and pharmaceutical channels.
-
MediPharm Labs Corp ( MEDIF ) is expanding its international medical cannabis market, with successful shipments to France and New Zealand, and continued growth in Germany.
-
The company maintains a strong balance sheet with $9.9 million in cash and virtually no debt, allowing flexibility for strategic opportunities.
-
Gross profit margin was 37%, among the higher levels achieved by the company, reflecting disciplined product mix management and cost control.
Negative Points
-
Revenue decreased to $9.0 million from $10.8 million in Q1 2025, reflecting typical first-quarter seasonality and market adjustments.
-
The Canadian medical cannabis revenue remained flat at $3.0 million, indicating challenges in domestic market growth.
-
The company faces near-term headwinds due to Veteran Affairs Canada's reimbursement changes, which could impact margins.
-
Net loss for the quarter was $0.9 million, compared to $0.4 million in the prior-year period, partly due to the absence of break fee income.
-
The U.S. Schedule III rescheduling of medical cannabis presents long-term opportunities but does not provide immediate P&L impact for MediPharm Labs Corp ( MEDIF ).
Q & A Highlights
Q: You announced that manufacturing is underway in Q2 for newly secured purchase agreements in France and Brazil. Realistically, when do you anticipate clearing final local import authorizations so that these agreements begin translating into recognized top-line revenue? Are we looking at a late Q3 or a Q4 event? A: Greg Hunter, Interim CEO and CFO: We expect to submit the regulatory dossier for France in Q2 2026 and are optimistic about receiving authorization later in the year. We made our first commercial shipments of medical cannabis oil in France in Q4 2025 and received a second purchase order in Q1 2026. We expect to start shipping against that in Q2 and anticipate additional shipments throughout 2026 as the market develops.
Q: The Veteran Affairs Canada price cutting reimbursement from $8.50 per gram down to $6 per gram goes into effect this quarter, Q2. Your Canadian medical cannabis revenue was flat at $3 million this quarter. What percentage of that domestic medical revenue is tied directly to Veteran Affairs patients, and what specific steps are being taken to insulate Canadian gross margins from this margin compression? A: Greg Hunter, Interim CEO and CFO: The reimbursement change is a near-term headwind for the industry. We anticipated this and implemented mitigation efforts, including a restructuring program in Q1 to save $1 million annually starting in Q2. We are focusing on product mix optimization and maintaining service to our veteran patient base, which is critical to us.
Q: For a long time, we've talked about MediPharm Labs and the potential pharma medical opportunities. With the U.S. rescheduling medical cannabis to Schedule III, how should we think about the sequence of that and conversations that you're having? A: Greg Hunter, Interim CEO and CFO: The U.S. rescheduling to Schedule III supports our longer-term pharmaceutical optionality. While this isn't an immediate impact on the P&L, it expands access to clinical research and pharmaceutical drug development. We are well-positioned with our FDA-inspected facility and drug establishment license. We are receiving more inbound calls from research universities interested in our capabilities.
Q: Are you getting more inbound calls in terms of partnerships due to the U.S. rescheduling of medical cannabis? A: Greg Hunter, Interim CEO and CFO: Yes, we are receiving more inbound calls, particularly from research universities looking at our capabilities to provide API. This is a combination of both inbound and outbound efforts to make potential partners aware of MediPharm's capabilities.
Q: What are the key takeaways from Q1 2026 for MediPharm Labs? A: Greg Hunter, Interim CEO and CFO: We executed key milestones across regulated international medical markets, delivered $9.0 million in revenue, maintained a 37% gross margin, and achieved positive adjusted EBITDA of $0.1 million. We exited the quarter with a strong balance sheet, including $9.9 million in cash and virtually no debt, positioning us well to fund the business and manage near-term headwinds.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
